ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 0119 • ACR Convergence 2022

    Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions Varies by Geographic Location of Residence

    Cheryl Barnabe1, Patrick McLane2, Nadia Luca1, Kelsey Chomistek1, Meghan Elliott1, Shanon McQuitty3, Steven Katz2, Eileen Davidson3, Clare Hildebrandt4, Katie Lin1, Brian Holroyd2 and Claire Barber1, 1University of Calgary, Calgary, AB, Canada, 2University of Alberta, Edmonton, AB, Canada, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada

    Background/Purpose: Rheumatology services in Canada are largely restricted to urban centres, resulting in significant access difficulties for residents of rural and remote locations. As a…
  • Abstract Number: 0862 • ACR Convergence 2022

    Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data

    Daniel Horton1, Yiling Yang2, Amanda Neikirk2, Cecilia Huang3, Stephen Crystal4, amy davidow5, Kevin Haynes6, Tobias Gerhard7, Carlos Rose8, Brian Strom9 and Lauren Parlett2, 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2HealthCore, Wilmington, DE, 3Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, 4Rutgers Center for Health Services Research, New Brunswick, NJ, 5New York University, New York, NY, 6Johnson & Johnson, Titusville, NJ, 7Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, 8Nemours, Chadds Ford, PA, 9Rutgers Biomedical and Health Sciences, Newark, NJ

    Background/Purpose: Limited information exists on COVID-19 pandemic-related changes in the management of rheumatic diseases in adults or children, besides what patients and families have reported.…
  • Abstract Number: 1299 • ACR Convergence 2022

    Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children

    Jo-Anne Marcuz1, Brian Feldman2, Y. Ingrid Goh3, Niina Kim4, Piya Lahiry5, Deborah Levy2, Elizaveta Limenis6, Jeanine McColl7, Christine O'Brien8, Susan Paetkau4, Shirley Tse2, Kristi Whitney8 and Ronald Laxer2, 1Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, 2Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, 4The Hospital for Sick Children, Toronto, ON, Canada, 5Division of Rheumatology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, ON, Canada, 6Division of Rheumatology, The Hospital for Sick Children; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 7Division of Rheumatology, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, 8Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children with significant morbidity that extends into adulthood. Despite advances in effective…
  • Abstract Number: 0137 • ACR Convergence 2022

    Polyarticular Arthritis and Osteolysis Caused by Mutations in the ASAH1 Gene: Farber Disease Clinical Presentations in the First-ever Natural History Study

    Alexander Solyom1, Kathleen Crosby2, Nils Confer2 and Jaime Lopez Valdez3, 1Aceragen, Basel, Switzerland, 2Aceragen, Durham, NC, 3Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico

    Background/Purpose: Farber disease is frequently misdiagnosed as polyarticular juvenile idiopathic arthritis or seronegative rheumatoid arthritis which leads to a delay in diagnosis for many patients.…
  • Abstract Number: 0863 • ACR Convergence 2022

    Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study

    Karen James1, George Tomlinson2, Tim Beukelman3, Laura Schanberg4, Anne Dennos5, VIncent Del Gaizo6, Marian Jelinek7, Erin Pfeifer8, Shalini Mohan9 and Yukiko Kimura10, 1University of Utah, Salt Lake City, UT, 2University of Toronto, Toronto, ON, Canada, 3Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, 7Childhood Arthritis and Rheumatology Research Alliance (CARRA), Duke, 8Genentech, Englewood, NJ, 9Genentech, San Diego, 10Hackensack Meridian Health, New York, NY

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a systemic autoinflammatory disease characterized by high fevers, rash and arthritis. Current treatment regimens often involve biologic (anti-IL-1…
  • Abstract Number: 1418 • ACR Convergence 2022

    Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry

    Colleen Correll1, Scott Stryker2, David Collier3, Anne Dennos4, Stephen Balevic5, Thomas Phillips5 and Tim Beukelman6, 1University of Minnesota, Minneapolis, MN, 2Amgen Inc., San Francisco, CA, 3Amgen Inc., Simi Valley, CA, 4Duke University, Durham, NC, 5Duke Clinical Research Institute, Durham, NC, 6Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL

    Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
  • Abstract Number: 0562 • ACR Convergence 2022

    Large-Scale Targeted Sequencing Study Links Systemic Juvenile Idiopathic Arthritis with Rare Variants of MEFV, LYST, STXBP2, UNC13D

    Mariana Correia Marques1, Danielle Rubin2, Emily Shuldiner2, Elizabeth Schmitz2, Elizabeth Baskin2, Andrew Patt3, Alexei Grom4, Dirk Foell5, Marco Gattorno6, John Bohnsack7, Rae Yeung8, Sampath Prahalad9, Elizabeth Mellins10, Jordi Antón11, Claudio Len12, Sheila Oliveira13, Patricia Woo14, Seza Ozen15, INCHARGE Consortium16 and Michael Ombrello17, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases / Children`s National Hospital, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 3National Center for Advancing Translational Sciences, Bethesda, MD, 4Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5University Hospital Münster, Münster, Germany, 6Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 7University of Utah, Salt Lake City, UT, 8The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 9Emory + Children's Pediatric Institute, Atlanta, GA, 10Stanford University, Stanford, CA, 11Pediatric Rheumatology Department. Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat, Spain, 12Universidade Federal de São Paulo, São Paulo, Brazil, 13Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, 14University College London, London, United Kingdom, 15Hacettepe University Faculty of Medicine, Ankara, Turkey, 16International Childhood Arthritis Genetics Consortium, Bethesda, MD, 17National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a genetically complex inflammatory condition. It can be marked by severe systemic inflammation that resembles the hereditary periodic…
  • Abstract Number: 0864 • ACR Convergence 2022

    Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort

    Esraa Eloseily1, Min-Lee Chang2, MaryEllen Riordan3, Alan Russell4, Marc Natter2, Yukiko Kimura5 and Grant Schulert6, 1Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Boston Children's Hospital, Boston, MA, 3Hackensack Meridian Health, Hackensack, NJ, 4Duke Clinical Research Institute, Duke, NC, 5Hackensack Meridian Health, New York, NY, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life threatening clinical problem, and currently affects as many as 1…
  • Abstract Number: 1679 • ACR Convergence 2022

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes

    Yukiko Kimura1, Sarah Ringold2, George Tomlinson3, Laura Schanberg4, Anne Dennos5, MaryEllen Riordan6, Vincent Del Gaizo7, Katherine Murphy8, Pamela Weiss9, Brian Feldman10, Mei Sing Ong11 and Marc Natter12, 1Hackensack Meridian Health, New York, NY, 2Janssen, Seattle, WA, 3University of Toronto, Toronto, ON, Canada, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Hackensack Meridian Health, Hackensack, NJ, 7CARRA, Inc, Washington, DC, 8CARRA, Inc, New Orleans, LA, 9Children's Hospital of Philadelphia, Glen Mills, PA, 10Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 11Harvard Pilgrim Institute, Boston, MA, 12Boston Children's Hospital, Boston, MA

    Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
  • Abstract Number: 0729 • ACR Convergence 2022

    Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network

    Y. Ingrid Goh1, Esi Morgan2, Meghan Ryan3, Beth Gottlieb4 and Nancy Pan5, 1Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, 2Seattle Children's Hospital, Seattle, WA, 3University of Minnesota, Vadnais Heights, MN, 4Cohen Children's Medical Center, Lake Success, NY, 5Hospital for Special Surgery, New York, NY

    Background/Purpose: Patients/proxies (Pts) complete patient reported outcome measures (PROMs) to inform their healthcare team about their health status. PROMs completed by Pts prior to their…
  • Abstract Number: 0867 • ACR Convergence 2022

    Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration

    Hiroto Nakano1, Emily Shuldiner2, Anne Hinks3, Marc Sudman4, Elaine Remmers5, Colleen Satorius6, Elizabeth Schmitz1, Victoria Arthur7, Patricia Woo8, Alexei Grom9, Dirk Foell10, John Bohnsack11, Marco Gattorno12, Seza Ozen13, Sampath Prahalad14, Rae Yeung15, Elizabeth Mellins2, Sheila Oliveira16, Jordi Antón17, Claudio Len18, Carol Lake19, Ly-Lan Bergeron20, Michelle Millwood21, Estefania de los santos21, Mariana Correia Marques22, Juvenile Arthritis Consortium for the Immunochip23, The Genomic Ascertainment Cohort Investigators24, INCHARGE Consortium25, Carl Langefeld26, Susan Thompson27, Wendy Thomson28 and Michael Ombrello1, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2Stanford University, Stanford, CA, 3The University of Manchester, Manchester, United Kingdom, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5National Human Genome Research Institute, Bethesda, MD, 6NHGRI, NIH, Bethesda, MD, 7Boston Children's Hospital, Boston, MA, 8University College London, London, United Kingdom, 9Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10University Hospital Münster, Münster, Germany, 11University of Utah, Salt Lake City, UT, 12Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 13Hacettepe University Faculty of Medicine, Ankara, Turkey, 14Emory + Children's Pediatric Institute, Atlanta, GA, 15The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 16Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, 17Pediatric Rheumatology Department. Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat, Spain, 18Universidade Federal de São Paulo, São Paulo, Brazil, 19NIH, Gaithersburg, MD, 20NIH/NIAMS, Vienna, VA, 21NIAMS, NIH, Bethesda, MD, 22National Institute of Arthritis and Musculoskeletal and Skin Diseases / Children`s National Hospital, Bethesda, MD, 23Juvenile Arthritis Consortium for the Immunochip, Bethesda, MD, 24The Genomic Ascertainment Cohort Investigators, Bethesda, MD, 25International Childhood Arthritis Genetics Consortium, Bethesda, MD, 26Wake Forest School of Medicine, Winston Salem, NC, 27Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, 28Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare inflammatory disease that causes spiking fever, skin rash, chronic arthritis, and inflammation of the heart and…
  • Abstract Number: 1934 • ACR Convergence 2022

    Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care

    Christina Ma1, Alessana Carmona2, Habeba Talaat2, Julie Herrington3, Tania Cellucci4, Stephanie Garner2, Mark Matsos2, KAREN BEATTIE2 and Michelle Batthish2, 1McMaster University, Canada, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3ACPAC, Hamilton, ON, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada

    Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity for patients with rheumatic disease. Consequently, there has…
  • Abstract Number: 0740 • ACR Convergence 2022

    Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study

    Carl Allen1, Shanmuganathan Chandrakasan2, Michael Jordan3, Jennifer Leiding4, Abiola Oladapo5, Priti Pednekar6, Kelly Walkovich7 and John Yee8, 1Baylor College of Medicine, Houston, TX, 2Emory University School of Medicine, Atlanta, GA, 3University of Cincinnati, Cincinnati, OH, 4Johns Hopkins University, Baltimore, MD, 5Swedish Orphan Biovitrum AB, Boston, MA, 6PRECISIONheor, Los Angeles, CA, 7University of Michigan Health, Ann Arbor, MI, 8Sobi - North America, Waltham, MA

    Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome caused by overproduction of proinflammatory cytokines, e.g., interferon gamma (IFNγ). Secondary HLH (sHLH), a subtype…
  • Abstract Number: 0868 • ACR Convergence 2022

    Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome

    Joy Um1, Douglas Einstadter2, Myung-Yong Um3 and Maria Antonelli1, 1Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, 2Center for Health Care Research and Policy, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, 3Department of Social Welfare, Sungkyunkwan University, Seoul, Republic of Korea

    Background/Purpose: Spondyloarthritis (SpA) consists of clinically and genetically related but phenotypically distinct disorders, including ankylosing spondylitis, enteropathic arthritis, psoriatic arthritis, reactive arthritis, and enthesitis-related arthritis…
  • Abstract Number: 1939 • ACR Convergence 2022

    Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases

    Merav Heshin-Bekenstein1, amit ziv2, NATASA TOPLAK3, Adi Miller Barmak4, Siman Lazauskas5, Danielle Kadishevich6, Efrat Ben Nun6, Esther Saiag7, Yonatan Butbul Aviel4, Gabi Shefer7, Sara Pel8, Ori Elkayam7 and Yosef Uziel9, 1Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, 2Meir Hospital, Kfar Saba, Israel, 3University of Ljubljana, Ljubljana, Slovenia, 4Rambam Medical Center, Haifa, Israel, 5Tel Aviv Medical Center, Tel Aviv, Israel, 6Meir Medical Center, Kfar Saba, Israel, 7Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 8Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, 9Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel

    Background/Purpose: Long-term data on the safety and dynamics of the immune response to the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune inflammatory rheumatic…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology